^
    Back
    Association details:
    Biomarker:ER-CCDC170 fusion
    Cancer:Breast Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Breast Cancer Res
    Title:

    Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

    Published date:
    08/08/2020
    Excerpt:
    More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib.
    DOI:
    10.1186/s13058-020-01325-3